Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

COSCIENS Biopharma (CSCIF) Price & Analysis

CSCIF Stock Chart & Stats

$6.10-$0.34(-5.28%)
At close: 4:00 PM EDT
$5$5.5$6$6.54 Aug18 Aug27 Aug16 Sep28 Sep13 Oct26 Oct
Day’s Range
$6.08 - $6.15
52-Week Range
$2.37 - $9.57
Previous Close
$6.44
Volume
N/A
Average Volume (3M)
503
Market Cap
$5.99M
Enterprise Value
$1.56M
Total Cash (Recent Filing)
$5.27M
Total Debt (Recent Filing)
$1.95M
Price to Earnings (P/E)
―
Beta
1.75
Next Earnings
Nov 17, 2026
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Improving Gross Margin

The substantial gross-margin improvement indicates better economics on the company’s current revenue base. If maintained, stronger margins can reduce the operating gap, improve the value of future growth, and support a more durable path toward eventual profitability.

Narrower Net Losses

Losses have narrowed materially across successive periods, showing meaningful operating improvement even though the company remains unprofitable. Continued progress could extend its financial runway and make future revenue growth more valuable by converting a larger share into earnings.

Conservative Leverage

The low debt-to-equity ratio provides a relatively conservative capital structure and reduces the immediate burden of interest and refinancing obligations. This gives management more flexibility to address operating weaknesses and fund development without relying heavily on leverage.

Bears Say

Persistent Unprofitability

Despite improved losses, the company remains deeply unprofitable and generates strongly negative returns on equity. The magnitude of these deficits means the business has not yet demonstrated a self-sustaining earnings model, leaving profitability improvement as a central fundamental risk.

Continued Cash Burn

Negative operating and free cash flow show that current operations continue to consume cash rather than fund the business internally. Although outflows improved from earlier periods, ongoing burn can constrain investment capacity and increase dependence on future financing or cash reserves.

Negative Revenue Growth

The negative reported revenue-growth figure signals that the company’s commercial expansion remains inconsistent, even alongside recent TTM stabilization. Weak or contracting sales can limit operating leverage, delay the path to profitability, and make margin improvements harder to sustain.

COSCIENS Biopharma News

CSCIF FAQ

What was COSCIENS Biopharma’s price range in the past 12 months?
COSCIENS Biopharma lowest stock price was $2.37 and its highest was $9.57 in the past 12 months.
What is COSCIENS Biopharma’s market cap?
COSCIENS Biopharma’s market cap is $5.99M.
When is COSCIENS Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were COSCIENS Biopharma’s earnings last quarter?
COSCIENS Biopharma released its earnings results on Aug 11, 2026. The company reported -$0.191 earnings per share for the quarter.
Is COSCIENS Biopharma overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does COSCIENS Biopharma pay dividends?
COSCIENS Biopharma does not currently pay dividends.
What is COSCIENS Biopharma’s EPS estimate?
COSCIENS Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSCIENS Biopharma have?
COSCIENS Biopharma has 996,394 shares outstanding.
What happened to COSCIENS Biopharma’s price movement after its last earnings report?
COSCIENS Biopharma reported an EPS of -$0.191 in its last earnings report. Following the earnings report the stock price went up 5.618%.
Which hedge fund is a major shareholder of COSCIENS Biopharma?
Currently, no hedge funds are holding shares in CSCIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology